PNP Biotech Insight: Why Polydatin Deserves to Be Re-Evaluated as an Upgrade Route for Resveratrol

In the resveratrol market, many products still focus their competition on “purity.” However, from PNP Biotech’s perspective, a high labeled content does not necessarily mean higher effective exposure once it enters the body. Human repeat-dose studies have shown that after oral administration of resveratrol, what mainly circulates in the body is often its metabolites, rather than consistently high levels of free resveratrol itself. In other words, simply comparing “on-paper purity” does not fully reflect the true in vivo performance of a raw material route.

For this reason, PNP Biotech believes that resveratrol in its glycoside form (resveratrol 3-O-β-D-glucoside, also known as Polydatin / Piceid) deserves to be re-evaluated. It is the glycoside form and natural precursor of resveratrol, and is more worthy of attention in terms of absorption, first-pass metabolism, and in vivo conversion pathways; what it represents is not merely a low-cost substitute, but an upgrade route built around in vivo exposure, herbal plant origin, differentiated positioning, and overall cost.

From “Purity Competition” to “In Vivo Exposure Competition”

Traditional resveratrol products are more likely to be positioned around the idea that “the higher the purity, the better.” But actual product value does not depend only on the number shown on the label. What matters more is what kind of absorption, transformation, and metabolic pathway the ingredient goes through after entering the body, and what kind of relevant exposure profile it ultimately forms. Human studies have already shown that resveratrol is rapidly metabolized after oral administration, which is why “high purity” does not automatically mean “better in vivo performance.”

For end brands, this means that the next step may not simply be to continue pursuing higher purity, but to re-evaluate: is there a route that is better suited for next-generation product development?

From PNP Biotech’s point of view, this shift is not only a technical judgment, but also a change in product logic. The future competitive focus of resveratrol-related products should not simply remain centered on higher purity, but rather move toward more practical product development questions: whether the ingredient can form more valuable relevant exposure after entering the body, whether it is more suitable for long-term product design, and whether it can find a new balance among origin expression, differentiation, and overall cost. This is also why PNP Biotech continues to encourage customers to re-evaluate the polydatin route.

Why Is Polydatin Worth Re-Evaluating?

1. It is the glycoside form of resveratrol, with a clear in vivo conversion pathway

Intestinal epithelial studies have shown that trans-piceid / polydatin can cross the intestinal epithelial cell layer at a relatively high rate and be deglycosylated into trans-resveratrol during the process. This means that polydatin is not an unfamiliar ingredient outside the resveratrol system, but a form directly related to resveratrol and capable of participating in its in vivo conversion. For product development, this is highly important, because it makes the “glycoside precursor–in vivo conversion” route a formulation pathway supported by evidence.

2. Oral animal comparative studies show that in vivo exposure deserves more attention at the same dosage

In an oral animal comparative study published in 2015, rats were given 200 mg/kg of polydatin and resveratrol, respectively. The results showed that under the study conditions, the average molar concentration of polydatin in serum reached 3.35 times and 4.28 times that of the corresponding resveratrol; at the same time, the two were mutually transformed in vivo, and in an oxidative stress model, polydatin also showed greater improvement in certain antioxidant indicators.

This indicates that, in current oral animal studies, the polydatin route demonstrates a higher trend of relevant in vivo exposure under the same dosage conditions. This is also one of the important reasons why it deserves to be re-evaluated as an upgrade route.

3. The human tolerance issues of high-dose resveratrol increase the need to reassess the route

In repeat-dose studies in healthy subjects, when 2.5 g or 5 g of resveratrol was taken daily, mild to moderate gastrointestinal symptoms occurred, including nausea, diarrhea, and abdominal discomfort. For end-product development, this means that evaluating a raw material route cannot focus only on “higher purity,” but must also consider dosage design, long-term tolerance, and product development space.

From this perspective, the significance of polydatin does not lie in simply claiming that it is “stronger,” but in the fact that it offers another route more worth testing: using the glycoside form of resveratrol to rebalance in vivo exposure, tolerance, and formulation efficiency.

4. Herbal plant origin is clearer, and the logic of origin communication and quality control is more straightforward

The resveratrol market includes plant extraction, fermentation, and other production routes, making origin expression relatively more complex; by contrast, as the glycoside form of resveratrol, polydatin is more easily and directly associated with the herbal plant extraction route, and is also more helpful in reducing origin disputes and concerns about adulteration. In comparison, resveratrol monomer usually has to bear more work in origin identification, quality verification, and market communication.

Although studies have explored the biosynthetic and fermentation routes of polydatin, current public information shows that these routes still face major limitations in synthesis efficiency and cost control, and their overall production cost is usually much higher than that of the plant extraction route. Therefore, they have not been chosen by the market.

Four Accounts: Why Is It Worth Re-Evaluating as an Upgrade Route?

Based on existing published research and product development logic, PNP Biotech prefers to evaluate the polydatin route from the following four dimensions, rather than simply treating it as a substitute for conventional resveratrol.

Efficacy Account

Polydatin not only has a clear in vivo conversion pathway, but in oral animal comparative experiments, under the same dosage conditions, its relevant in vivo exposure was higher than that of resveratrol, and the average molar concentration of the relevant components in serum could reach 3.35 times and 4.28 times that of the corresponding resveratrol.

Tolerance Account

Human studies of high-dose resveratrol have already indicated a gastrointestinal burden. Using the polydatin route may reduce reliance on high-dose resveratrol regimens while maintaining a higher trend of relevant in vivo exposure.

Differentiation Account

As a clearly plant-derived ingredient, polydatin does not require repeated distinction among plant extraction, fermentation, or synthetic routes during procurement and use; at the same time, current research also suggests that it deserves more attention in terms of absorption, first-pass metabolism, and in vivo conversion pathways.

Cost Account

Based on the in vivo exposure advantage reflected in the aforementioned animal studies, using polydatin may reduce raw material input. From this perspective, compared with directly using resveratrol, the overall cost can be reduced by at least more than one-third.

Conclusion

For PNP Biotech, what is truly worth paying attention to about resveratrol in its glycoside form (resveratrol 3-O-β-D-glucoside, also known as polydatin) is not merely whether it can replace conventional resveratrol, but whether it offers an upgrade route that is better suited for next-generation product development. Existing published research has already provided several clear signals: it has a clear in vivo conversion pathway, shows a higher trend of relevant in vivo exposure in oral animal experiments, and also has further evaluation value in terms of herbal plant origin expression, differentiated positioning, and overall cost balance.

It is precisely for this reason that PNP Biotech is continuously encouraging customers and partners to re-examine this route. We believe that the significance of polydatin is not to repeat the competitive logic of conventional resveratrol, but to help end brands shift from “continuing to compete on purity” to “re-evaluating which route is more suitable for balancing in vivo exposure, product expression, differentiation, and overall cost.”

If your product is currently using resveratrol, or if you are considering upgrading, replacing, or optimizing costs, PNP Biotech is also willing to provide sample support and further supply communication to assist you in evaluating the feasibility of this route.

Reference Studies and Regulatory Links

Brown VA, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers.
https://pubmed.ncbi.nlm.nih.gov/20935227/

Henry-Vitrac C, et al. Transport, Deglycosylation, and Metabolism of Trans-piceid by Intestinal Epithelial Cells.
https://pubmed.ncbi.nlm.nih.gov/17009167/

Wang HL, et al. Comparative studies of polydatin and resveratrol on mutual transformation and antioxidative effect in vivo.
https://pubmed.ncbi.nlm.nih.gov/25981921/

PubChem: Polydatin / Piceid.
https://pubchem.ncbi.nlm.nih.gov/compound/Piceid

FDA: New Dietary Ingredient (NDI) Notification Process.
https://www.fda.gov/food/dietary-supplements/new-dietary-ingredient-ndi-notification-process

FDA: Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes for Dietary Supplements.
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements